1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies
4-5 November 2016
Hyatt Regency Paris Étoile
3, Place du Général Koenig
Paris, 75017, France
Tel +33 (0) 1 40 68 12 34
Hotel Information Link
There has been tremendous progress in the treatment of lymphoid malignancies in recent years. Our ability to characterize these tumors has evolved considerably based on sophisticated molecular techniques, which are used to individualize risk stratification and management. Advances in basic science have resulted in rational targeted and immunotherapeutic drug development in the field. This is great news for patients, but has added to the complexity of managing these malignancies in contemporary clinical practice settings. Given the pace at which practice-changing evidence continues to emerge, clinicians face the constant challenge to maintain state-of-the-art care in managing patients with these tumors. Although optimized outcomes depend on the incorporation of novel strategies and proactive mitigation of predictable treatment-related adverse events, the ability to do so depends most on the ability of practitioners to place landmark trial findings into clinical context.
We are excited to announce the 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies! Also known as Paris Lymphoma™, this highly practical and interactive multi-day program will improve patient care for the clinician who manages patients with lymphoid malignancies. At this year’s Paris Lymphoma™, leading international experts will participate in cutting-edge lectures and panels that will discuss recent data sets. Most importantly, the meeting will allow for interactive discussion and for participants to engage directly with renowned faculty to share their perspectives, personal experiences, and methods to address clinical challenges in the management of lymphoid malignancies.
Target AudienceThis educational activity is directed toward healthcare professionals based outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.) involved in the treatment and management of patients with hematologic malignancies.
Educational ObjectivesAt the conclusion of this activity, you should be better prepared to:
- Describe current and evolving genomic and molecular biomarkers that can be used to stratify risk and inform clinical decision making in the management of hematologic malignancies
- Assess landmark clinical trial results in the context of how they impact evolving clinical practice paradigms and can be applied to personalize care and optimize outcomes
- Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of hematologic malignancies so as to maximize treatment outcomes
- Discuss effective strategies to assess and address nonadherence to oral oncolytic therapies in the treatment and management of hematological malignancies
- Evaluate recent clinical trial findings concerning novel compounds or strategies to manage hematologic malignancies
- Consider the therapeutic implications of emerging data on evolving treatment paradigms for patients with hematologic tumors
Physicians' Education Resource®, LLC' 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignances is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The '1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies' is designated for a maximum of (or 'for up to') 12 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.
Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York, USA
Gilles A. Salles, MD, PhD
Université Claude Bernard Lyon- 1
Hospices Civils de Lyon
You must be logged in to PER to register for this meeting
Or Register for PER now